Comparative Pharmacokinetics and Pharmacodynamics of LY2963016 and US-Approved Lantus After Single-Dose Subcutaneous Administration to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 08 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History